Stoke Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Stoke Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue | 13,817,000 | 158,569,000 | 22,614,000 | 4,894,000 | 4,831,000 | 4,216,000 | 2,802,000 | 3,308,000 | -2,481,000 | 5,152,000 | 3,268,000 | 2,905,000 | 3,231,000 | 3,000,000 | |||||||||||
yoy | 186.01% | 3661.12% | 707.07% | 47.94% | -294.72% | -18.17% | -14.26% | 13.87% | -176.79% | 71.73% | |||||||||||||||
qoq | -91.29% | 601.20% | 362.08% | 1.30% | 14.59% | 50.46% | -15.30% | -233.33% | -148.16% | 57.65% | 12.50% | -10.09% | 7.70% | ||||||||||||
operating expenses: | |||||||||||||||||||||||||
research and development | 25,855,000 | 32,676,000 | 23,423,000 | 22,205,000 | 21,136,000 | 22,368,000 | 21,778,000 | 20,271,000 | 20,551,000 | 19,631,000 | 21,060,000 | 20,109,000 | 18,358,000 | 18,309,000 | 15,802,000 | 14,358,000 | 14,095,000 | 9,913,000 | 8,904,000 | 8,109,000 | 7,968,000 | 7,215,000 | 7,089,000 | 6,518,000 | 6,023,000 |
general and administrative | 15,262,000 | 14,653,000 | 12,844,000 | 12,692,000 | 13,037,000 | 10,220,000 | 10,610,000 | 10,271,000 | 10,230,000 | 10,211,000 | 9,384,000 | 9,944,000 | 10,111,000 | 9,486,000 | 8,724,000 | 8,325,000 | 7,934,000 | 6,914,000 | 5,682,000 | 5,602,000 | 5,044,000 | 4,520,000 | 3,979,000 | 3,324,000 | 2,422,000 |
total operating expenses | 41,117,000 | 47,329,000 | 36,267,000 | 34,897,000 | 34,173,000 | 32,588,000 | 32,388,000 | 30,542,000 | 30,781,000 | 29,842,000 | 30,444,000 | 30,053,000 | 28,469,000 | 27,795,000 | 24,526,000 | 22,683,000 | 22,029,000 | 16,827,000 | 14,586,000 | 13,711,000 | 13,012,000 | 11,735,000 | 11,068,000 | 9,842,000 | 8,445,000 |
income from operations | -27,300,000 | 111,240,000 | -13,653,000 | -30,003,000 | -29,342,000 | -28,372,000 | -29,586,000 | -27,234,000 | -33,262,000 | -24,690,000 | -27,176,000 | -27,148,000 | -25,238,000 | -24,795,000 | -24,526,000 | -22,683,000 | -22,029,000 | -16,827,000 | -14,586,000 | -13,711,000 | -13,012,000 | -11,735,000 | -11,068,000 | -9,842,000 | -8,445,000 |
yoy | -6.96% | -492.08% | -53.85% | 10.17% | -11.79% | 14.91% | 8.87% | 0.32% | 31.79% | -0.42% | 10.80% | 19.68% | 14.57% | 47.35% | 68.15% | 65.44% | 69.30% | 43.39% | 31.79% | 39.31% | 54.08% | ||||
qoq | -124.54% | -914.77% | -54.49% | 2.25% | 3.42% | -4.10% | 8.64% | -18.12% | 34.72% | -9.15% | 0.10% | 7.57% | 1.79% | 1.10% | 8.13% | 2.97% | 30.91% | 15.36% | 6.38% | 5.37% | 10.88% | 6.03% | 12.46% | 16.54% | |
operating margin % | -197.58% | 70.15% | -60.37% | -613.06% | -607.37% | -672.96% | -1055.89% | -823.28% | 1340.67% | -479.23% | -831.58% | -934.53% | -781.12% | -826.50% | |||||||||||
other income: | |||||||||||||||||||||||||
interest income | 3,789,000 | 2,889,000 | 2,970,000 | 3,545,000 | 3,695,000 | 2,426,000 | 2,587,000 | 2,651,000 | 2,567,000 | 2,103,000 | 1,479,000 | 995,000 | 544,000 | 104,000 | 36,000 | 44,000 | 34,000 | 18,000 | 10,000 | 11,000 | 50,000 | 674,000 | 904,000 | 1,236,000 | 629,000 |
other income | 28,000 | 28,000 | 201,000 | 28,000 | -48,000 | -428,000 | 41,000 | 41,000 | 41,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | 28,000 | 16,000 | 15,000 | 16,000 | 3,000 | 22,000 | 4,000 | 2,000 | -3,000 |
total other income | 3,817,000 | 2,917,000 | 3,171,000 | 3,573,000 | 3,647,000 | 1,998,000 | 2,628,000 | 2,692,000 | 2,608,000 | 2,145,000 | 1,521,000 | 1,037,000 | 586,000 | 146,000 | 78,000 | 86,000 | 62,000 | 34,000 | 25,000 | 27,000 | 53,000 | 696,000 | 908,000 | 1,238,000 | 626,000 |
income before income taxes | -23,483,000 | 114,157,000 | |||||||||||||||||||||||
benefit from income taxes | 1,278,000 | ||||||||||||||||||||||||
net income | -23,483,000 | 112,879,000 | -10,482,000 | -26,430,000 | -25,695,000 | -26,374,000 | -26,958,000 | -24,542,000 | -30,654,000 | -22,545,000 | -25,655,000 | -26,111,000 | -24,652,000 | -24,649,000 | -24,448,000 | -22,597,000 | -21,967,000 | -7,819,000 | |||||||
yoy | -8.61% | -527.99% | -61.12% | 7.69% | -16.18% | 16.98% | 5.08% | -6.01% | 24.35% | -8.54% | 4.94% | 15.55% | 12.22% | ||||||||||||
qoq | -120.80% | -1176.88% | -60.34% | 2.86% | -2.57% | -2.17% | 9.84% | -19.94% | 35.97% | -12.12% | -1.75% | 5.92% | 0.01% | 0.82% | 8.19% | 2.87% | |||||||||
net income margin % | -169.96% | 71.19% | -46.35% | -540.05% | -531.88% | -625.57% | -962.10% | -741.90% | 1235.55% | -437.60% | -785.04% | -898.83% | -762.98% | -821.63% | |||||||||||
net income per share | -0.17 | -0.47 | -0.46 | -0.57 | -0.6 | -0.55 | -0.69 | -0.53 | -0.65 | -0.66 | -0.63 | -0.66 | -0.67 | -0.61 | -0.6 | -0.46 | -0.42 | -0.41 | -0.39 | -0.34 | -0.09 | -0.26 | -1.54 | ||
basic | -0.4 | 1.95 | |||||||||||||||||||||||
diluted | -0.4 | 1.9 | |||||||||||||||||||||||
weighted-average common shares outstanding: | |||||||||||||||||||||||||
basic | 58,353,855 | 57,862,674 | |||||||||||||||||||||||
diluted | 58,353,855 | 59,398,600 | |||||||||||||||||||||||
comprehensive income: | |||||||||||||||||||||||||
other comprehensive gain: | |||||||||||||||||||||||||
unrealized gain on marketable securities | 200 | 47 | -317 | 181 | -15 | 24 | 123 | 232 | 219 | 577 | -383.75 | -427 | -516 | -5.5 | 20 | ||||||||||
total other comprehensive gain | 200 | 47 | -317 | 181 | -15 | 24 | |||||||||||||||||||
comprehensive income | -23,283 | 112,926 | |||||||||||||||||||||||
net income per share | -0.17 | -0.47 | -0.46 | -0.57 | -0.6 | -0.55 | -0.69 | -0.53 | -0.65 | -0.66 | -0.63 | -0.66 | -0.67 | -0.61 | -0.6 | -0.46 | -0.42 | -0.41 | -0.39 | -0.34 | -0.09 | -0.26 | -1.54 | ||
weighted-average common shares outstanding, basic and diluted | 56,341,074 | 55,765,948 | 46,246,889 | 44,266,017 | 44,188,464 | 42,536,474 | 39,420,310 | 39,258,358 | 37,448,301 | 36,759,319 | 36,708,188 | 36,643,205 | 33,273,597 | 33,054,656 | 32,897,395 | 32,707,647 | 5,083,620 | ||||||||
comprehensive loss: | |||||||||||||||||||||||||
comprehensive loss | -10,799 | -26,249 | -25,710 | -26,350 | -26,835 | -24,310 | -30,435 | -21,968 | -25,127 | -26,538 | -25,244 | -25,165 | -24,594 | -22,577 | -21,925 | ||||||||||
total other comprehensive loss | 257 | 232 | 219 | 577 | 528 | -427 | -592 | -516 | -146 | 20 | -42 | ||||||||||||||
other comprehensive loss: | |||||||||||||||||||||||||
unrealized loss on marketable securities | -592 | -42 | |||||||||||||||||||||||
net income and comprehensive loss | -16,793,000 | -14,561,000 | -13,684,000 | -12,959,000 | -11,039,000 | -10,160,000 | -8,604,000 |
We provide you with 20 years income statements for Stoke Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Stoke Therapeutics stock. Explore the full financial landscape of Stoke Therapeutics stock with our expertly curated income statements.
The information provided in this report about Stoke Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.